Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2023 08:30 ET | Source: Future Market Insights Global and Consulting Pvt. Ltd.

Nasal Polyposis Treatment Market to reach US$ 8.8 billion by 2033, Corticosteroids to Constitute 55% of all Treatments: Future Market Insights, Inc. Report

NEWARK, Del, March 27, 2023 (GLOBE NEWSWIRE) -- The global Nasal Polyposis Treatment Market is expected to reach US$ 4.6 billion in value terms by 2023-end and is projected to rise at a CAGR of 6.7%...
March 16, 2023 10:30 ET | Source: Allied Market Research

Global Nasal Spray Market Is Expected to Reach $16.9 Billion by 2031: Allied Market Research

Portland, OR, March 16, 2023 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Nasal Spray Market generated $9.2 billion in 2021, and is estimated to reach...
February 28, 2023 16:30 ET | Source: Optinose, Inc.

Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results

YARDLEY, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
July 08, 2022 07:00 ET | Source: Optinose, Inc.

Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program

Company previously announced positive top-line results from both ReOpen1 and ReOpen2, the landmark trials evaluating XHANCE as a treatment for chronic sinusitis Multiple secondary endpoints from...
November 15, 2021 16:26 ET | Source: Optinose, Inc.

Optinose Reports Third Quarter 2021 Financial Results and Recent Operational Highlights

Third quarter 2021 XHANCE net revenue of $22 million increased 41% compared to third quarter 2020 Third quarter 2021 XHANCE prescriptions increased 25% from third quarter 2020 Conference call and...
August 11, 2021 07:00 ET | Source: Optinose, Inc.

Optinose Reports Second Quarter 2021 Financial Results and Recent Operational Highlights

Second quarter 2021 XHANCE net revenue of $18.4 million increased 79% compared to second quarter 2020 Second quarter 2021 XHANCE prescriptions increased 33% from second quarter 2020 Conference call...
April 28, 2021 08:30 ET | Source: Optinose, Inc.

Optinose Announces Reporting Date for First Quarter 2021 Financial Results and Upcoming Healthcare Conference Presentation

Conference Call and Webcast to be held May 5, 2021 at 8:00 a.m. Eastern Time Company to Present at the RBC Capital Markets Global Healthcare Conference on May 18, 2021 YARDLEY, Pa., April 28, 2021...